# US 8,278,278 B2 · Cell proliferation reducing cancer specific PCNA peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,278 B2
- Document ID: US8278278B2
- Status: Granted
- Kind: B2
- Application number: 12/900,202
- Filed: 2010-10-07
- Published: 2011-03-31
- Granted: 2012-10-02
- Earliest claimed: 2008-07-24
- Assignees: Indiana University Research and Technology Corporation
- Inventors: Linda H. Malkas; Robert J. Hickey
- Web page: https://patentgrep.com/patent/US8278278B2

## CPC

- A61K 38/1709: {from mammals}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 33/243: Platinum; Compounds thereof
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 14/4738: {Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR (cell cycle dependent kinases C12N9/12)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Cell-permeable caPCNA-derived peptides and their variants serve as therapeutic compositions to reduce the proliferation of cancerous cells and also augment cytotoxic effects of chemotherapeutics.

## Claims

### Claim 1

A therapeutic composition for reducing cellular proliferation of malignant cells, the composition comprising a peptide molecule fused or linked to a cell penetrating peptide, wherein the peptide molecule comprises an amino acid sequence selected from the group consisting of LGIPEQEY (SEQ ID NO: 1), LAIPEQEY (SEQ ID NO: 2), LGIAEQEY (SEQ ID NO: 3), LGIPAQEY (SEQ ID NO: 4), LGIPEAEY (SEQ ID NO: 5), LGIPEQAY (SEQ ID NO: 6), LGIAEAEY (SEQ ID NO: 7), LGIPEAAY (SEQ ID NO: 8), LGIAEQAY (SEQ ID NO: 9), and LGIAEAAY (SEQ ID NO: 10), and wherein the cell penetrating peptide comprises an amino acid sequence selected from the group consisting of RRRRRRR (SEQ ID NO: 11), RRRRRRRR (SEQ ID NO: 12), RRRRRRRRR (SEQ ID NO: 13), RRRRRRRRRR (SEQ ID NO: 14), RRRRRRRRRRR (SEQ ID NO: 15), RQIKIWFQNRRMKWKK (SEQ ID NO: 16), GRKKRRQRRRPPQ (SEQ ID NO: 17), GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 18), and GRKKRRQRRR (SEQ ID NO: 19).

### Claim 2 (depends on 1)

The composition of claim 1, wherein the amino acid sequence of the cell penetrating peptide comprises one or more amino acid D-isomers.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the cell penetrating peptide is covalently linked or conjugated to the peptide molecule.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the cell penetrating peptide is recombinantly fused with the peptide molecule.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the peptide molecule further comprises a cell surface targeting factor.

### Claim 6 (depends on 1)

The composition of claim 1, further comprising a chemotherapeutic agent.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the chemotherapeutic agent is a DNA damaging agent.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the DNA damaging agent is selected from the group consisting of doxorubicin, irinotecan, cyclophosphamide, chlorambucil, melphalan, methotrexate, cytarabine, fludarabine, 6-mercaptopurine, 5-fluorouracil, capecytabine, cisplatin, carboplatin, oxaliplatin, and a combination thereof.

### Claim 9

A method In vitro of reducing cellular proliferation or inducing cell death of a cancer cell or a pre-malignant cell expressing cancer-specific proliferating cell nuclear antigen (caPCNA), the method comprising administering a therapeutically effective amount of a composition comprising a peptide molecule fused or linked to a cell penetrating peptide, wherein the peptide molecule comprises an amino acid sequence selected from LGIPEQEY (SEQ ID NO: 1), LAIPEQEY (SEQ ID NO: 2), LGIAEQEY (SEQ ID NO: 3), LGIPAQEY (SEQ ID NO: 4), LGIPEAEY (SEQ ID NO: 5), LGIPEQAY (SEQ ID NO: 6), LGIAEAEY (SEQ ID NO: 7), LGIPEAAY (SEQ ID NO: 8), LGIAEQAY (SEQ ID NO: 9), and LGIAEAAY (SEQ ID NO: 10), and wherein the cell penetrating peptide comprises an amino acid sequence selected from the group consisting of RRRRRRR (SEQ ID NO: 11), RRRRRRRR (SEQ ID NO: 12), RRRRRRRRR (SEQ ID NO: 13), RRRRRRRRRR (SEQ ID NO: 14), RRRRRRRRRRR (SEQ ID NO: 15), RQIKIWFQNRRMKWKK (SEQ ID NO: 16), GRKKRRQRRRPPQ (SEQ ID NO: 17), GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 18), and GRKKRRQRRR (SEQ ID NO: 19), to contact the cancer or pre-malignant cell expressing caPCNA.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cancer or premalignant cell has a mutation in a DNA repair protein.

### Claim 11 (depends on 10)

The method of claim 10, wherein the DNA repair protein participates in homologous recombination.

### Claim 12 (depends on 11)

The method of claim 11, wherein the protein is BRCA1.

### Claim 13 (depends on 9)

The method of claim 9, further comprising administering a chemotherapeutic agent.

### Claim 14 (depends on 13)

The method of claim 13, wherein the chemotherapeutic agent is a DNA damaging agent.

### Claim 15 (depends on 14)

The method of claim 14, wherein the DNA damaging agent is selected from the group consisting of doxorubicin, irinotecan, cyclophosphamide, chlorambucil, melphalan, methotrexate, cytarabine, fludarabine, 6-mercaptopurine, 5-fluorouracil, capecytabine, cisplatin, carboplatin, oxaliplatin, and combinations thereof.

### Claim 16 (depends on 9)

The method of claim 9, wherein the cancer or pre-malignant cell is a breast, colon, lung, ovary, prostate, or blood cell.
